Accueil   Diary - News   All news MaaT Pharma announces the creation of its Scientific Advisory Board (SAB)

MaaT Pharma announces the creation of its Scientific Advisory Board (SAB)

Logo MaâT 4e versionMaaT Pharma, a leader in the intestinal microbiome industry and pioneer in Autologous Faecal Microbiotherapy, today announced the creation of its international Scientific Advisory Board of acknowledged experts in the fields of intestinal microbiome, haematology, gastroenterology, bacteriology and clinical trial methodology.

 

 The purpose of the Board will be to assist MaaT Pharma in its development, to expand and enrich its medical vision in such areas as the correction of dysbiosis and its associated complications, the eradication of Multi-Drug Resistant Bacteria, and the prevention of nosocomial diseases. It will notably formulate recommendations to enable MaaT Pharma to expand the use of its autologous microbiotherapy technology to the development of solutions for the correction of dysbiosis in designated therapeutic areas.

 



 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree